CFDE Data Portal | Search MRPL2

	Label	Description
	MRPL2 associations Collection (Entity type)	Associations for MRPL2_associations
	MRPL2 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	MRPL2 Gene (Entity type)	ENSG00000112651 - mitochondrial ribosomal protein L2
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE74251 decitabine MCF-7 0 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212330 azacitidine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE165548 gemcitabine 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE224311 3 V 4 CHAETOCIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

MRPL2 associations

Associations for MRPL2_associations

MRPL2 associations.tsv

A file from IDG as part of the Harmonizome project

MRPL2

ENSG00000112651 - mitochondrial ribosomal protein L2

GSE252944 AKT inhibition 10 v 15 human dn

A Gene Set from LINCS

GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

A Gene Set from LINCS

GSE74251 decitabine MCF-7 0 v 3 human dn

A Gene Set from LINCS

GSE212330 azacitidine 1 v 0 human dn

A Gene Set from LINCS

GSE165548 gemcitabine 2 v 5 human up

A Gene Set from LINCS

GSE224311 3 V 4 CHAETOCIN HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.